- Home
- ZYME vs SRCE Comparison
ZYME vs SRCE Comparison
Compare ZYME & SRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZYME | SRCE |
|---|---|---|
| Founded | 2003 | 1863 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2022 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ZYME | SRCE |
|---|---|---|
| Price | $23.23 | $66.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | $32.75 | ★ $73.25 |
| AVG Volume (30 Days) | ★ 484.1K | 83.9K |
| Earning Date | 03-30-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 2.31% |
| EPS Growth | 5.81 | ★ 19.59 |
| EPS | N/A | ★ 6.41 |
| Revenue | ★ $76,304,000.00 | N/A |
| Revenue This Year | $63.10 | $9.25 |
| Revenue Next Year | $93.26 | $3.29 |
| P/E Ratio | ★ N/A | $10.84 |
| Revenue Growth | ★ 0.38 | N/A |
| 52 Week Low | $9.03 | $52.14 |
| 52 Week High | $28.49 | $71.98 |
Technical Indicators
Market Signals| Indicator | ZYME | SRCE |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 44.01 |
| Support Level | $22.22 | $58.47 |
| Resistance Level | $23.66 | $70.15 |
| Average True Range (ATR) | 0.84 | 1.72 |
| MACD | 0.15 | -0.43 |
| Stochastic Oscillator | 45.85 | 5.35 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About SRCE 1st Source Corporation
1st Source Corp, along with its subsidiary, offers banking services. The bank provides Commercial, Agricultural, and Real Estate Loans, which are given to privately owned business clients mainly located within the regional market areas, Consumer Services that consist of the full range of consumer banking products and services, Trust and Wealth Advisory Services, and Insurance services to individuals and business clients. Its Specialty Finance Group offers financing services for construction equipment, new and pre-owned private and cargo aircraft, and various vehicle types for fleet purposes.